Literature DB >> 2990657

Teratoma with malignant transformation in germ cell tumors in men.

T Ahmed, G J Bosl, S I Hajdu.   

Abstract

Pathology reports of over 580 male patients with germ cell tumors treated between 1972 and 1982 were screened for teratomas in which malignant transformation was apparent. The diagnosis was established in 17 cases. The median age was 28 years (range, 14-52). For patients with disease limited to the testis, the median survival has not been reached, with all five patients surviving disease-free at 22+ to 120+ months. Among the 12 patients with metastatic disease, the median survival was 30.5 months (range, 12-69). All 12 patients were treated with cisplatin-containing regimens. Six had complete responses either to chemotherapy alone or to chemotherapy plus resection of residual disease. Four of the six complete responders relapsed, and three died of progressive disease. One patient with sarcomatous differentiation was treated with a doxorubicin-based regimen and had a partial remission, which lasted 8 months. Teratoma with malignant transformation, when found in metastatic sites, appeared to be a poor prognostic pathologic variant in male patients with germ cell tumors.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2990657     DOI: 10.1002/1097-0142(19850815)56:4<860::aid-cncr2820560426>3.0.co;2-3

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  32 in total

Review 1.  Late relapse of testicular cancer.

Authors:  Martin E Lipphardt; Peter Albers
Journal:  World J Urol       Date:  2004-04-03       Impact factor: 4.226

2.  Testicular germ cell tumors with sarcomatous components: an analysis of 33 cases.

Authors:  Charles C Guo; Metin Punar; Alejandro Luiña Contreras; Shi-Ming Tu; Louis Pisters; Pheroze Tamboli; Bogdan Czerniak
Journal:  Am J Surg Pathol       Date:  2009-08       Impact factor: 6.394

Review 3.  Teratoma with somatic-type malignant components of the testis. A review and an update.

Authors:  Gregor Mikuz; Maurizio Colecchia
Journal:  Virchows Arch       Date:  2012-05-24       Impact factor: 4.064

Review 4.  Therapeutic strategies for uncommon testis cancer histologies: teratoma with malignant transformation and malignant testicular sex cord stromal tumors.

Authors:  Mounsif Azizi; Ahmet M Aydin; Salim K Cheriyan; Charles C Peyton; Matthew Montanarella; Scott M Gilbert; Wade J Sexton
Journal:  Transl Androl Urol       Date:  2020-01

5.  Intrapulmonary cystic teratoma mimicking malignant pulmonary neoplasm.

Authors:  Abhishek Chandrakant Sawant; Ajay Kandra; Swapna Reddy Narra
Journal:  BMJ Case Rep       Date:  2012-08-14

6.  Practice Patterns and Impact of Postchemotherapy Retroperitoneal Lymph Node Dissection on Testicular Cancer Outcomes.

Authors:  Solomon L Woldu; Joseph A Moore; Bo Ci; Yuval Freifeld; Timothy N Clinton; Ahmet M Aydin; Nirmish Singla; Krabbe Laura-Maria; Ryan C Hutchinson; James F Amatruda; Arthur Sagalowsky; Yair Lotan; Yull Arriaga; Vitaly Margulis; Yang Xie; Aditya Bagrodia
Journal:  Eur Urol Oncol       Date:  2018-06-06

7.  Somatic malignant transformation in a sacrococcygeal teratoma in a child and the use of F18FDG PET imaging.

Authors:  R Howman-Giles; A J A Holland; D Mihm; J M Montfort; S Arbuckle; S Kellie
Journal:  Pediatr Surg Int       Date:  2007-09-09       Impact factor: 1.827

8.  Teratoma with malignant transformation in the anterior mediastinum: a case report.

Authors:  J I Jung; S H Park; J G Park; S H Lee; K Y Lee; S T Hahn
Journal:  Korean J Radiol       Date:  2000 Jul-Sep       Impact factor: 3.500

9.  Embryonal rhabdomyosarcoma arising from a mediastinal teratoma: an unusual case report.

Authors:  Young-Joon Ryu; Su Hyun Yoo; Min Jung Jung; Sejin Jang; Kyung-Ja Cho
Journal:  J Korean Med Sci       Date:  2013-03-04       Impact factor: 2.153

10.  Malignant transformation of testicular teratoma: a chemoresistant phenotype.

Authors:  Philippe E Spiess; Louis L Pisters; Ping Liu; Curtis A Pettaway; Ashish M Kamat; Jose A Gomez; Nizar M Tannir
Journal:  Urol Oncol       Date:  2008-01-14       Impact factor: 3.498

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.